Gershon, AA, Takahashi, M, Seward, J. Varicella vaccine. In: Plotkin, SA, Orenstein, WA, Offit, PA, eds. Vaccines, 5th edn. Philadelphia: Saunders, 2007, pp. 915–958.
Arvin, AM. Varicella-zoster virus. Clinical Microbiology Review
1996; 9: 361–381.
Lee, BW. Review of varicella zoster seroepidemiology in India and Southeast Asia. Tropical Medicine & International Health
1998; 3: 886–890.
Wharton, M. The epidemiology of varicella-zoster virus infections. Infectious Disease Clinics of North America
1996; 10: 571–581.
Reynolds, MA, et al.
Varicella seroprevalence in the U.S.: data from the National Health and Nutrition Examination Survey, 1999–2004. Public Health Reports
2010; 125: 860–869.
Nardone, A, et al.
The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine
2007; 25: 7866–7872.
Guris, D, et al.
Changing varicella epidemiology in active surveillance sites – United States, 1995–2005. Journal of Infectious Diseases
2008; 197 (Suppl. 2): S71–S75.
Lopez, AS, et al.
Varicella-related hospitalizations in the United States, 2000–2006: the 1-dose varicella vaccination era. Pediatrics
2011; 127: 238–245.
Marin, M, Zhang, JX, Seward, JF. Near elimination of varicella deaths in the US after implementation of the vaccination program. Pediatrics
2011; 128: 214–220.
Maple, PA, et al.
Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay. Clinical and Vaccine Immunology
2006; 13: 214–218.
Schmid, DS, Jumaan, AO. Impact of varicella vaccine on varicella-zoster virus dynamics. Clinical Microbiology Reviews
2010; 23: 202–217.
Kilgore, PE, et al.
Varicella in Americans from NHANES III: implications for control through routine immunization. Journal of Medical Virology
2003; 70 (Suppl. 1): S111–S118.
Bartoloni, A, et al.
Seroprevalence of varicella zoster and rubella antibodies among rural populations of the Chaco region, south-eastern Bolivia. Tropical Medicine & International Health
2002; 7: 512–517.
Garnett, GP, et al.
The age of infection with varicella-zoster virus in St Lucia, West Indies. Epidemiology and Infection
1993; 110: 361–372.
Longfield, JN, et al.
Varicella outbreaks in Army recruits from Puerto Rico. Varicella susceptibility in a population from the tropics. Archives of Internal Medicine
1990; 150: 970–973.
Withers, BG, et al.
Vaccine-preventable disease susceptibility in a young adult Micronesian population. The Southeast Asian Journal of Tropical Medicine and Public Health
1994; 25: 569–574.
Kudesia, G, et al.
Changes in age related seroprevalence of antibody to varicella zoster virus: impact on vaccine strategy. Journal of Clinical Pathology
2002; 55: 154–155.
Zhou, F, et al.
An economic analysis of the universal varicella vaccination program in the United States. Journal of Infectious Diseases
2008; 197 (Suppl. 2): S156–164.
Marin, M, Meissner, HC, Seward, JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics
2008; 122: e744–751.
Rozenbaum, MH, et al.
Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Review of Vaccines
2008; 7: 753–782.